Malvern Instruments Presentation Shows Power of Near-infrared Chemical Imaging in Quality by Design
News May 05, 2008
A new freely downloadable presentation available via the Malvern Instruments website, highlights how SyNIRgi, the company’s near infrared chemical imaging (NIR-CI) system, can provide the data and product understanding required for Quality by Design. To download the presentation visit http://www.brainshark.com/malvern/NIR-CI_pharma.
‘Near infrared imaging of pharmaceuticals and Quality by Design’ looks at how this measurement technology can help answer the questions of “What? How much? And Where?” It presents a variety of applications in the pharmaceutical industry and a discussion of how to derive statistically meaningful, reproducible and quantitative results.
According to Malvern, SyNIRgi identifies, quantifies and locates chemical species within a sample. This information provides insight into product performance, optimizing design space definition and specification setting. Analytical times are short and no sample preparation is required, making the system a ‘go to’ option for QbD related studies.
With SyNIRgi a researcher can track water gradients in a tablet during hydration, rather than simply monitoring average water content. The distribution of active pharmaceutical ingredients (API) can be studied to assess the efficacy of blending or interactions with excipients. Coating quality – thickness, homogeneity – can be statistically measured. In each case the result is greater product and process understanding.
SyNIRgi is fully automated with the capability to analyze powders, granules, tablets or complete blister packs, in minutes. In excess of 80,000 spectra are collected from across the surface of the sample for each measurement. Advanced statistical analysis techniques, accessed via ISys, a user-friendly software package, extract relevant chemical and morphological information.
Research Team Discovers Compound that Stops Cancer From SpreadingNews
Using a mouse model, OHSU physician-scientists lead effort to hone a drug that inhibits cancer cells from spreading to other areas in the body.READ MORE
Synthetic DNA Shuffling Enzyme Outpaces Natural CounterpartNews
A new synthetic enzyme, crafted from DNA rather than protein, flips lipid molecules within the cell membrane, triggering a signal pathway that could be harnessed to induce cell death in cancer cells. Researchers say their lipid-scrambling DNA enzyme is the first in its class to outperform naturally occurring enzymes – and does so by three orders of magnitudeREAD MORE
PhoreMost and o2h Discovery Collaborate to Progress First-in-Class Drug Discovery ProgramsNews
PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, announced it has entered into a collaboration with o2h discovery (o2h), an Anglo-Indian medicinal chemistry company that has in-house capability to take drug discovery programmes to the IND filing stage.READ MORE